355 Detectability of medication errors in older people prior to potentially preventable admissions Detectability of medication errors The MEs identified at hospital readmission by the DRA adjudication teams were used as primary source for conducting this substudy. The relationship between the identified MEs and the detectability of these MEs at the time of the in-hospital medication review during index hospitalisation was retrospectively explored based on three screening questions: 1. Was the ME present at the time of the in-hospital medication review? MEs were considered present if the inappropriate prescription (i.e., a drug omission identified as underuse or a prescribed drug identified as overuse/misuse) and the medical condition related to the ME were both present during the in-hospital medication review. MEs that were not present during the in-hospital medication review were considered not detectable. 2. Was the ME detected by STOPP/START? MEs were considered detected if a STOPP/START signal was generated by the CDSS during the in-hospital medication review, regardless of whether this signal resulted in a change in medication regimen recommended by the pharmacotherapy teams. 3. Was a change in medication regimen recommended by the pharmacotherapy teams? Recommendations for changes in medication regimen by the pharmacotherapy teams were based on the acceptance of STOPP/START signals; if no STOPP/START signal was generated, such recommendations were based on expert opinion (i.e., non-STOPP/START-based recommendation). Three theoretical examples of ME detectability at the time of the in-hospital medication review are outlined in the Text Box. Outcomes The primary outcome of this study was the detectability of MEs identified at readmission with a STOPP/START-based in-hospital medication review at the time of the index hospitalisation prior to a potentially preventable DRA. The outcome included; 1) the proportion of MEs that was present and therefore detectable during the in-hospital medication review. The total number of MEs was used as the denominator. The total number of MEs identified at readmission was defined by the DRA adjudication teams; 2) the proportion of MEs that was detected by STOPP/START during the in-hospital medication review. The number of present 4
RkJQdWJsaXNoZXIy MTk4NDMw